MCID Incorporated into Efficacy Evaluation Criteria

The Ministry of Food and Drug Safety has specified the clinical trial review standards for digital therapeutics targeting seven conditions, including Attention-Deficit/Hyperactivity Disorder (ADHD) and depressive disorders. The agency has enhanced the efficacy evaluation criteria so that the therapeutic effects can be assessed at a level perceptible to actual patients, and has presented standards for multi-center clinical trials and follow-up observations, aiming to reduce trial-and-error for developers.


MFDS Specifies Clinical Trial Standards for Digital Therapeutics Targeting Seven Conditions Including ADHD View original image

According to the Ministry on September 10, the National Institute of Food and Drug Safety Evaluation has revised the “Guidelines for Preparing Digital Therapeutic Clinical Trial Protocols” for seven indications, such as nicotine use disorder and alcohol use disorder. The targeted indications are: ▲nicotine use disorder ▲alcohol use disorder ▲panic disorder ▲depressive disorder ▲eating disorder ▲attention-deficit/hyperactivity disorder (ADHD) ▲mild cognitive impairment.


This revision was made to reflect accumulated clinical trial protocol review cases since the implementation of the “Digital Medical Products Act,” as well as the latest international trends. The goal is to reduce trial-and-error during clinical trial design by developers and to shorten the preparation period.


The most significant change is the clarification of standards for evaluating the efficacy of digital therapeutics. The new standards require developers to establish efficacy evaluation variables based on scientific evidence and to incorporate the “Minimum Clinically Important Difference” (MCID), in line with the latest review standards. MCID refers to the minimum change that allows a patient to actually perceive an improvement in their condition, going beyond a statistically significant result in a clinical trial.


Additionally, the criteria to enhance the reliability of clinical trials have been supplemented. Examples now include multi-center trials conducted across multiple medical institutions, and follow-up observation periods to verify whether the therapeutic effect is maintained after treatment. Furthermore, the guideline’s items and terminology have been updated to reflect the enactment and recent amendments of the Digital Medical Products Act and its subordinate regulations.


The Ministry expects that these revisions will improve developers’ understanding of the latest review standards and enhance the completeness of clinical trial designs. It anticipates that the preparation period for digital therapeutic clinical trials will be shortened, thereby accelerating market entry.



A Ministry official stated, “We will continue to establish practical guidelines that reflect the rapidly changing environment and feedback from the field,” adding, “We plan to take the lead in facilitating the swift market entry of digital therapeutics and in creating a safe usage environment.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing